Hidradenitis Suppurativa Foundation News

As significant news occurs, HSF will post updates as quickly as possible.

Announcing New 2018 Danby Hidradenitis Suppurativa Research Grant Program

Request for Proposals

Purpose: The Hidradenitis Suppurativa Foundation (HSF) is seeking grant applications that encourage research into the disease hidradenitis suppurativa (HS). The goal is to stimulate the development of new research programs in the field of hidradenitis suppurativa capable of competing for long-term funding from the National Institutes of Health or other agencies in the future.

Anticipated number of awards: 1-2 new grants may be awarded in 2018. Awards are contingent upon the availability of funds and the receipt of sufficiently meritorious applications.

Budget: Applicants may request up to $10,000 (direct costs only) per year.

Application Instructions: The HSF Grant application must be submitted through email to executivedirectorhsf@gmail.com as a single pdf. The application should follow the Format outlined below and include a project proposal of no more than five (5) pages.

Important dates: Applications must be received by Dec. 1st, 2018 at 5 P.M. EST.

Award notifications will be made no later than May 1, 2019, to start July 1, 2019.

Project period: The project period for this Request for Proposals is one year, from July 1, 2019 – June 30, 2020. All funds are to be spent within this period.

Eligibility: The principal investigator must be personally and actively responsible for the conduct of the proposed research, and eligible to apply for research grants under the guidelines of the applicant’s host institution. The HSF does not fund projects that are part of the NIH intramural research program or awards to private foundations without an academic affiliation to dermatology.

Review Criteria:

Reviewers will be asked to base their evaluations on the criteria listed below.

  • Relevance to hidradenitis suppurativa
  • Innovation
  • Likelihood of leading to additional funding
  • Strategy, methodology and analyses are well-reasoned and appropriate to accomplish the aims
  • Ability of investigator to accomplish aims

Potential problems, alternative strategies, and benchmarks for success are presented

Reporting requirements: Within 60 days of completing the approved project, the grantee is required to submit a written report summarizing their research experience and findings. The grantee must also present the work at an approved national or international meeting to be held within two years of funding. If an approved project cannot be completed as originally proposed or within the time limits mandated the grantee must immediately contact the HSF.

Questions: For more information on HSF Grants please send an email to executivedirectorhsf@gmail.com

2018 Danby Hidradenitis Suppurativa Research Grant Application

The application should follow the following format, with a minimum of 0.5 inch margins and minimum of 11-point font size, single spaced.

A. TITLE PAGE: Include the grant title, principal investigator’s name and affiliations.

B. ABSTRACT: Summarize the proposed research for a scientific audience. Abstract must not exceed 350 words.

C. LAYMAN’S STATEMENT: Summarize the proposed research for a non-scientific audience. This statement should describe the research question, the aims of the project, and the project’s significance with respect to HS. Layman’s statement must not exceed 200 words.

D. BUDGET: Each grant is limited to $10,000 for one year. Indirect costs are not allowed. Provide a budget summary, including a concise statement of how you propose to allocate funds (amount and for what purpose), List all personnel to be included in the project and their anticipated support.

E. BIOGRAPHICAL SKETCH(ES): Use the NIH format to provide a biographical sketch of the proposal’s principal investigator and any co-investigators who will play a significant role on the project. Each biographical sketch must not exceed 5 pages.

F. LETTER(S) OF SUPPORT: Applicants may use this space to provide letters of support from collaborators or supporting people/facilities/resources who will contribute to the proposed research. If the applicant is a postdoctoral fellow, a letter of support from the applicant’s immediate supervisor must be provided.

G. RESEARCH PROPOSAL: Research proposals must include the following four sections, maximum five (5) pages:

1. Specific aims: The goals of this one-year proposal should be succinctly stated. What hypothesis is to be tested? What do you intend to accomplish? Because this funding is intended to initiate projects that would qualify for additional future funding, please differentiate between the immediate aims of this project and related aims that would follow in year two or three.

2. Background and significance: Why is the research important? Evaluate existing knowledge in the field and specifically identify the possible contributions that your investigation may make.

3. Preliminary data/studies: Describe published or unpublished data that support your hypothesis, specific aims and/or experimental design.

4. Experiment design: Describe the experimental design, the procedures to be used and the manner in which the data will be analyzed. Descriptions of established lab procedures are not necessary.

H. REFERENCES: List of references cited.

I. HUMAN SUBJECT PROTECTION: Describe samples, risks, adequacy of protection against risks, and potential benefit. Applications related to research on human subjects must be approved by the institutional review board prior to the initiation of successful awards.

J. ANIMAL STUDIES: Applications that involve research on animals must demonstrate their relevance to clinical dermatology. Application involving animal studies must be approved by an appropriate institutional committee prior to the initiation of successful awards.

______

AbbVie has launched the AbbVie Immunology Scholarship, which is designed to provide financial support for exceptional students living with inflammatory diseases*, including  psoriasis or hidradenitis suppurativa (HS), as they pursue their higher education goals.

Below is a brief overview of the scholarship for your reference.

UCSF Dermatology Post-Doctoral Fellowship in Clinical Research

The UCSF Department of Dermatology’s Program for Clinical Research is thrilled to announce the availability of a 1-2 year postdoctoral research fellowship for starting July 1st 2018.

The primary areas of interest include epidemiology, public health and investigator-initiated clinical trials. The postdoc would join a dynamic research team that works on a wide range of topics: inflammatory skin diseases, hidradenitis suppurativa, atopic dermatitis, geriatric dermatology, skin cancer, and the use of social media in medicine.

Eligibility Criteria:

– US Citizen or US Permanent Resident

– Must have an MD or PhD by June 30th 2018

Research experience in study design and analysis and the use of statistical software programs is preferred. Applicants from groups traditionally underepresented in medicine (UIM) are encouraged to apply.

Interested candidates should submit their CV, a 1-page letter summarizing their professional goals and research experience and 3 reference letters by March 24th 2018 to Jeanette.torres@ucsf.edu.

ABBVIE IMMUNOLOGY SCHOLARSHIP OVERVIEW

  • The scholarship is available to students living with inflammatory diseases*, including psoriasis or HS, who are seeking an undergraduate or graduate degree from an accredited US university/college or trade school, and who plan to enroll for the 2018-2019 school year.
  • Scholarships of up to $15,000 each will be awarded, dependent upon the type of degree pursued.
  • Applicants will be judged based on academic excellence, extracurricular activities, written response to an essay question, and letter of reference.
  • Key dates and deadlines are as follows:

Applications will be made available on November 13, 2017 on www.AbbVieImmunologyScholarship.com.

Applications must be submitted by 12 p.m. CST on January 9, 2018.

Award recipients will be notified by April 18, 2018.

2018 Danby HSF Research Grant Funding Opportunities-Grant applications awarded.  Winners to be announced soon.

July 21, 2017: The Hidradenitis Suppurativa Foundation (HSF) is seeking grant applications that encourage research into the disease hidradenitis suppurativa (HS). The goal is to stimulate the development of new research programs in the field of HS capable of competing for long-term funding from the National Institutes of Health or other agencies in the future.

If you would like to submit your proposal, please follow the instructions here: 2018-danby-hsf-research-grant-program.

Anticipated number of awards: 1-2 new grants may be awarded in 2018. Awards are contingent upon the availability of funds and the receipt of sufficiently meritorious applications.

Budget: Applicants may request up to $10,000 (direct costs only) per year.

Last year, Dr. Amanda Nelson won this prestigious grant for the following project.

The cause of hidradenitis suppurativa (HS) is unknown. HS affects 1-4% of the population (3.2-12.8 million people in the USA) and is a chronic, debilitating inflammatory skin appendage disorder, primarily occurring in the axillae (armpits) and groin with no known treatment or cure. Our laboratory is focused on understanding the cause and progression of HS. As very little is understood about this disease, we will use state-of-the-art 3D imaging technology to examine the skin architecture and skin appendages in HS skin to determine if there is a structural deficit within the skin of HS patients. In addition, we will investigate the presence of aberrant skin stem cell populations in HS lesions that may contribute to the chronic nature of this disease.

May 30, 2017:  Both the states of Georgia and Michigan have proclaimed June 5-11, 2017 as Hidradenitis Suppurativa Awareness Week.

Click on these links for the signed proclamations: Georgia Proclamation and Michigan Proclamation.

HS Foundation Participation at IDEOM (International Dermatology Outcome Measures)

New York, New York – October 15th, 2016

The HS Foundation National Coordinator of Advocacy and Support, HSF Physician Board Members, along with Hope for HS, represented the interests of patients and physicians at the IDEOM conference for HS.  Physicians specializing in HS treatment, along with six HS patients, HS Advocates and Industry were present to develop consensus on the domains to be used in outcome measures for HS.

Why was the IDEOM event important? Actually, it is more than important, it is a milestone for HS. Outcome measures are used in clinical trials. Clinical trials do not always mean trials of a drug, as this can relate to quality of life, surgery or procedures, drugs (topical, oral, injectables, infusions, etc), and even diet or alternative medicine. This group decides by means of a consensus on the standardized outcomes or endpoints that are looked at to determine results for a trial.

Establishing standardized tools for HS trials is a tremendous milestone. This shows that HS is being recognized as a disease that needs more research and needs agreed upon tools, with input from both physicians and patients, to get the most valuable data from a trial.

Now that the domains have been established, the tools within the domains can be developed. The HS Foundation and Hope for HS will continue involvement in the process of developing outcome measures for HS.

We would like to thank IDEOM for their diligent work in advancing knowledge of HS.

ideom

HS Working Group at IDEOM, New York, New York – October 15th, 2016